Search Result

Results for "

PD-1/PD-L1 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PD-1/PD-L1 (183) Akt (3) AMPK (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (14) Aryl Hydrocarbon Receptor (2) Bacterial (1) Bcl-2 Family (1) Biochemical Assay Reagents (1) Btk (2) c-Fms (1) c-Kit (2) c-Myc (1) Cadherin (1) Caspase (1) CCR (1) CD3 (1) COX (2) CTLA-4 (3) CXCR (4) Cyclic GMP-AMP Synthase (1) DGK (2) Discoidin Domain Receptor (2) DNA/RNA Synthesis (1) EGFR (2) Endogenous Metabolite (1) Epoxide Hydrolase (1) ERK (1) Eukaryotic Initiation Factor (eIF) (1) Exosomes (1) FLT3 (3) Fungal (1) FXR (1) GSK-3 (1) HBV (3) HDAC (4) Histone Acetyltransferase (1) Histone Demethylase (1) IFNAR (3) IGF-1R (1) IKK (1) IKZF Family (3) Indoleamine 2,3-Dioxygenase (IDO) (1) Interleukin Related (6) Itk (2) JAK (1) JNK (1) LAG-3 (3) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (2) MAP4K (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) Molecular Glues (3) mTOR (1) NAMPT (1) NF-κB (2) p38 MAPK (1) PAK (1) PARP (1) PERK (1) Phosphatase (2) PI3K (3) PROTACs (2) Ras (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Sec61 (2) SHP1 (1) STAT (2) STING (2) TAM Receptor (2) Target Protein Ligand-Linker Conjugates (2) TGF-beta/Smad (1) Tim3 (1) TNF Receptor (2) Transmembrane Glycoprotein (4) Trk Receptor (2) VEGFR (6) VISTA (1)
By Research Areas:	Cancer (188) Cardiovascular Disease (4) Infection (12) Inflammation/Immunology (65) Metabolic Disease (3) Neurological Disease (1)
Click Chemistry:	DBCO (1) Azide (1)
Oligonucleotides:	Aptamers (1)

209

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Oligonucleotides

Targets Recommended: PD-1/PD-L1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9902

Pembrolizumab Maximum Cited Publications 30 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-19991

BMS-1 Maximum Cited Publications 31 Publications Verification PD-1/PD-L1 inhibitor 1	PD-1/PD-L1 Apoptosis	Inflammation/Immunology Cancer
BMS-1 is an inhibitor of the *PD-1/PD-L1* protein/protein interaction (IC₅₀ between 6 and 100 nM) .

HY-P9902A

Pembrolizumab (anti-PD-1) 5 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .

HY-19745

BMS-202 20+ Cited Publications	PD-1/PD-L1 Apoptosis	Cancer
BMS-202 is a potent and nonpeptidic PD-1/PD-L1 complex inhibitor with an IC₅₀ of 18 nM and a K_D of 8 μM. BMS-202 binds to PD-L1 and blocks human PD-1/PD-L1 interaction. BMS-202 has antitumor activity .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1* Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer .

HY-P991628

SSGJ-707 PF-08634404	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and *PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1* signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by *PD-L1* expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .

HY-102011

BMS-1166 5+ Cited Publications	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-1166 is a potent *PD-1/PD-L1* immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC₅₀ of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-116274

BMS-8 1 Publications Verification	PD-1/PD-L1	Cancer
BMS-8 inhibits the *PD-1/PD-L1* interaction with IC₅₀ of 7.2 μM. BMS-8, binds directly to PD-L1 and induces formation of PD-L1 homodimers, which in turn prevents the interaction with PD-1 .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-131183

PROTAC PD-1/PD-L1 degrader-1	PROTACs PD-1/PD-L1	Inflammation/Immunology
PROTAC PD-1/PD-L1 degrader-1, a *PD-1/PD-L1* PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC₅₀ of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .

HY-P991078

Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting *CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1* internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-144258

PD-1/PD-L1-IN-14	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of *PD-1/PD-L1* interactions, with an IC₅₀ of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .

HY-150879

BMS-37	PD-1/PD-L1 Ligands for Target Protein for PROTAC	Cancer
BMS-37 is a *PD-1/PD-L1* immune checkpoint inhibitor with an IC₅₀ towards the PD-L1/PD-1 complex in the range of 18 to 200 nM. BMS-37 shows unspecific toxicity against modified Jurkat T cells with an EC₅₀ between 3 and 6 µM. BMS-37 can be used for the study of the PD-L1-induced exhaustion of T-cells or as PD-L1 ligand to synthesize PROTAC molecules .

HY-101058A

PD1-PDL1-IN 1 TFA	PD-1/PD-L1	Inflammation/Immunology Cancer
PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 TFA is useful as immune modulator .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-145774

PD-1/PD-L1-IN-23	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-23 is a potent and orally active inhibitor of *PD-1/PD-L1. PD-1/PD-L1-IN-23* is an ester proagent of L7. L7 is a benzo[c][1,2,5]oxadiazole derivative and biologically evaluated as inhibitors of PD-L1. PD-1/PD-L1-IN-23 displays significant antitumor effects in tumor models of syngeneic and PD-L1 humanized mice .

HY-101097

PD-1-IN-17	PD-1/PD-L1	Cancer
PD-1-IN-17 is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM .

HY-120402

BMS-200	PD-1/PD-L1	Inflammation/Immunology
BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC₅₀ of 80 nM. BMS-200 can induce dimerization of PD-L1 .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-155101

PD-L1-IN-3	PD-1/PD-L1	Cancer
PD-L1-IN-3 (Compound 4a) is a compound that targets PD-1/PD-L1, the IC₅₀ value and EC₅₀ value is 4.97nM and 2.70 μM for inhibit *PD-L1* and Jurkat T cells, respectively. PD-L1-IN-3 can bind PD-L1 dimer to prevent PD-1 binding to PD-L1, therefore blocking PD-1 signaling. PD-L1-IN-3 can be used for lung cancer and melanoma diseases research .

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-134886

PD-1-IN-24	PD-1/PD-L1	Cancer
PD-1-IN-24 (compound 1) is an orally active *PD-1* inhibitor .

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and *PD-1. RC148 blocks PD-1-PD-L1* and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .

HY-155959

PD-1/PD-L1-IN-33	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-33 (Compound N11) is a *PD-1/PD-L1* inhibitor. PD-1/PD-L1-IN-33 inhibits PD-1 and PD-L1 interaction with an IC₅₀: 6.3 nM. PD-1/PD-L1-IN-33 promotes T-cell proliferation, activation, and infiltration into tumor spheres. PD-1/PD-L1-IN-33 has immunomodulatory and anticancer activity .

HY-152240

PD-1/PD-L1-IN-29	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-29 (S4-1) is a potent *PD-1/PD-L1* inhibitor with an IC₅₀ value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity .

HY-155847

LYP-IN-3	Phosphatase PD-1/PD-L1	Inflammation/Immunology Cancer
LYP-IN-3 is a selective, orally active and reversible lymphoid-tyrosine phosphatase (LYP) inhibitor (IC₅₀ = 2.55 μM, Ki = 0.93 μM). D34 exhibits high selectivity of PTP1B, PTPN12, PTPN5 and SSH2. LYP-IN-3 regulates the T-cell receptor (TCR) signaling by specifically inhibiting LYP. LYP-IN-3 does not significantly inhibit MC38 cell viability; its anti-tumor effect stems from immune regulation. LYP-IN-3 can significantly upregulate *PD-L1* or *PD-1* expression in different immune cells. LYP-IN-3 facilitates T-cell infiltration and enhances T-cell functions. LYP-IN-3 synergizes with *PD-L1* blockade can significantly improve colorectal tumor regression. LYP-IN-3 can be used for the study of colorectal cancer .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can block the binding of PD-1* to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-128605

PD-1-IN-22	PD-1/PD-L1	Cancer
PD-1-IN-22 is a potent programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction inhibitor with an IC₅₀ of 92.3 nM .

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein** inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .

HY-145240

eIF4E-IN-1	Eukaryotic Initiation Factor (eIF)	Infection Cancer
eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y) .

HY-W018597

2-Chloro-N-methylethanamine hydrochloride	Biochemical Assay Reagents	Others
2-Chloro-N-methylethanamine hydrochloride is a nitro compound that can be used to synthesize PD-1 inhibitors .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-172200

PD-L1/HDAC6-IN-1	PD-1/PD-L1 HDAC	Inflammation/Immunology Cancer
PD-L1/HDAC6-IN-1 is an orally active dual inhibitor of *PD-L1* and HDAC6, with IC₅₀ values of 26.8 nM and 78 nM, respectively. PD-L1/HDAC6-IN-1 binds to human and murine PD-L1 proteins with high affinity, while it reduces STAT3 phosphorylation and downregulates PD-L1 expression by inhibiting HDAC6, thus blocking the PD-1/PD-L1 interaction. PD-L1/HDAC6-IN-1 exhibits potent anti-tumor activity in a mouse melanoma model. PD-L1/HDAC6-IN-1 is suitable for research on tumor immune regulation related to melanoma .

HY-162343

PD-1/PD-L1-IN-41	PD-1/PD-L1	Inflammation/Immunology Cancer
PD-1/ PD-L1-in-41 (Compound 5c) is a *PD-L1* and *PD-1* inhibitor with IC₅₀ value of 10.2 nM .

HY-101058

PD1-PDL1-IN 1	PD-1/PD-L1	Inflammation/Immunology
PD1-PDL1-IN 1 (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. PD1-PDL1-IN 1 is useful as immune modulator .

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 .

Cat. No.	Product Name

HY-L031

Small Molecule Immuno-Oncology Compound Library

788 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 788 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

HY-L109

Protein-protein Interaction Inhibitor Library

797 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 797 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P10375

BMS-986189	PD-1/PD-L1	Inflammation/Immunology Cancer
BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC₅₀ of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 .

HY-122542B

PPACK TFA 2 Publications Verification	Ligands for E3 Ligase Molecular Glues IKZF Family	Cardiovascular Disease
PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (T_reg) into effector-like T cells, enhances CD8 ⁺ T cell responses, and modulates the T_eff:T_reg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of T_reg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1 .

HY-P3139

TPP-1	PD-1/PD-L1	Cancer
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .

HY-P4072A

(D)-PPA 1 TFA	PD-1/PD-L1	Cancer
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P3143

BMSpep-57	PD-1/PD-L1	Cancer
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-103048A

PD-1/PD-L1-IN 3 TFA	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .

HY-P2478

Human PD-L1 inhibitor V	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .

HY-P2477

Human PD-L1 inhibitor IV	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor IV, a polypeptide, is a competitive *human PD-1* protein** inhibitor with a K_d value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1 .

HY-P10217

PD-1/PD-L1-IN-42	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between **PD-1 and PD-L1, with an EC₅₀** of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .

HY-103048

PD-1/PD-L1-IN 3	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the *PD-1/PD-L1* and *CD80/PD-L1* interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC₅₀s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .

HY-P4072

(D)-PPA 1	PD-1/PD-L1	Cancer
(D)-PPA 1 is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 serves as a potent *PD-1/PD-L1* inhibitor. (D)-PPA 1 binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy .

HY-P2478A

Human PD-L1 inhibitor V TFA	PD-1/PD-L1	Inflammation/Immunology
Human PD-L1 inhibitor V TFA, a *human PD-1* protein binding peptide with a K_d** value of 3.32 μM. Human PD-L1 inhibitor V TFA inhibit the interaction of hPD-1/hPD-L1 .

HY-P3139A

TPP-1 TFA	PD-1/PD-L1	Cancer
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (K_D=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function .

HY-P3143A

BMSpep-57 hydrochloride	PD-1/PD-L1	Cancer
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC₅₀ of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with K_ds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .

HY-P10838

PL120131	PD-1/PD-L1 Apoptosis	Cancer
PL120131 is a *PD-1* antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 can be used in research related to breast cancer and various malignant tumors .

HY-P10826

PD-1/PD-L1 inhibitory peptide C8	PD-1/PD-L1	Cancer
PD-1/PD-L1 inhibitory peptide C8 is inhibits *PD-1/PD-L1* interaction, promotes the activation of CD8+ and CD4+ T cells, and increases the IFN-γ secretion. PD-1/PD-L1 inhibitory peptide C8 exhibits antitumor efficacy in mouse model .

HY-P10838A

PL120131 acetate	PD-1/PD-L1 Apoptosis	Cancer
PL120131 acetate is a *PD-1* antagonist, can specifically blocking the interaction between PD-1 and PD-L1, thereby effectively inhibiting the PD-1-mediated apoptosis signaling pathway. PL120131 acetate rescues lymphocytes from apoptosis, maintains the survival and activity of T cells, and induces cytotoxic T lymphocytes to exert killing effects and recognize macrophages and dendritic cells. PL120131 acetate can be used in research related to breast cancer and various malignant tumors .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9902

Pembrolizumab Maximum Cited Publications 30 Publications Verification MK-3475; Lambrolizumab	PD-1/PD-L1	Cancer
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.

HY-P99675

Ivonescimab 1 Publications Verification AK112	PD-1/PD-L1 VEGFR	Cancer
Ivonescimab (AK112) is a *PD-1/VEGF* bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL) .

HY-P9902A

Pembrolizumab (anti-PD-1) 5 Publications Verification MK-3475 (anti-PD-1); Lambrolizumab (anti-PD-1)	PD-1/PD-L1	Cancer
Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody and *PD-1* inhibitor. Pembrolizumab produces *PD-1* blockade, preventing PD-L1 and PD-L2 from connecting to *PD-1. This avoids the uncontrolled regulation of T cells on cells that normally express PD-1* .

HY-P99145

Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) 10+ Cited Publications	PD-1/PD-L1	Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) is an anti-mouse *PD-L1/B7-H1* IgG2b antibody inhibitor derived from host rat. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) blocks PD-1 signaling. Anti-Mouse PD-L1/B7-H1 Antibody (10F.9G2) can be used for the research of cancer, such as colon cancer .

HY-P9997

Rosnilimab ANB030	PD-1/PD-L1	Inflammation/Immunology
Rosnilimab (ANB030) is a *PD-1* agonist IgG1 monoclonal antibody. Rosnilimab can inhibit T cell proliferation, the secretion of inflammatory cytokines, and reduce CD4 and CD8 T cells with high *PD-1* expression. Rosnilimab can be used in the research of inflammatory diseases such as colitis and rheumatoid arthritis .

HY-P99048

Sintilimab 1 Publications Verification IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99144A

Anti-Mouse PD-1 Antibody (S-5001) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (S-5001) is a selective inhibitor targeting *PD-1, blocking the PD-1/PD-L1* immune checkpoint axis through competitive binding to *PD-1. Anti-Mouse PD-1* Antibody (S-5001) works by reversing the tumor immunosuppressive microenvironment and reactivating the anti-tumor activity of cytotoxic T lymphocytes. It can be used in research on tumors such as melanoma and HPV-positive oropharyngeal squamous cell carcinoma. Anti-Mouse PD-1 Antibody (S-5001) is often combined with photothermal therapy, chemotherapy, etc., to enhance efficacy .

HY-P990788

Anti-Mouse PD-1 Antibody (29F.1A12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (29F.1A12) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (29F.1A12) blocks the binding of PD-1 to its two ligands, PD-L1 and PD-L2. Anti-Mouse PD-1 Antibody (29F.1A12) can be used for the researches of cancer and immunology, such as CT26 tumor and pancreatic cancer .

HY-P991628

SSGJ-707 PF-08634404	PD-1/PD-L1 VEGFR	Cancer
SSGJ-707 (PF-08634404) is a bispecific antibody targeting VEGF and *PD-1. SSGJ-707 exerts dual anti-tumor effects by neutralizing VEGF and blocking the PD-1* signaling pathway. SSGJ-707 can be combined with platinum-based chemotherapy to inhibit advanced non-small cell lung cancer (NSCLC), and its inhibitory effect is not limited by *PD-L1* expression levels. In the HARMONi-2 trial, the objective response rate of SSGJ-707 correlates with the PD-L1 tumor proportion score, and the incidence of grade ≥3 adverse events is comparable to that of Inetetamab (HY-P99969). SSGJ-707 is being extensively investigated for a variety of malignancies including advanced NSCLC, colorectal cancer and small cell lung cancer .

HY-P9971

Camrelizumab 4 Publications Verification SHR-1210; INCSHR1210	PD-1/PD-L1	Cancer
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to *PD-1. Camrelizumab binds PD-1* at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC₅₀ of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .

HY-P99166

Vudalimab XMAB-20717	PD-1/PD-L1 CTLA-4	Inflammation/Immunology Cancer
Vudalimab is a potent dual *PD-1* and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation .

HY-P99499

Cetrelimab JNJ 63723283; JNJ 3283	PD-1/PD-L1 Interleukin Related TNF Receptor	Cancer
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting *PD-1. Cetrelimab binds PD-1* (K_d=1.72 nM, HEK293) to block the interaction of *PD-1* with *PD-L1* and PD-L2 (IC₅₀s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-P990169

Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12)	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse/Human phosphorylated PD-1/CD279 Antibody (407.6G12) is a mouse-derived IgG2a κ type antibody inhibitor, targeting to mouse/human phosphorylated *PD-1/CD279. Anti-Mouse/Human phosphorylated PD-1/CD279* Antibody (407.6G12) can detect the phosphorylated form of the PD-1 ITSM by both western blot and flow cytometry .

HY-P990824

Anti-Mouse PD-1 Antibody (J43) 1 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Anti-Mouse PD-1 Antibody (J43) is a kind of armenian hamster IgG antibody inhibitor, targeting to mouse *PD-1. Anti-Mouse PD-1* Antibody (J43) inhibits the interaction of PD-1 with PD-L1. Anti-Mouse PD-1 Antibody (J43) can be used for the researches of cancer and immunology, such as breast cancer and colon cancer .

HY-P991078

Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 (LALA-PG) Antibody (RMP1-14) is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P990690

Volrustomig MEDI-5752	PD-1/PD-L1 CTLA-4	Cancer
Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting *CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1* internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 ⁺ T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 ⁺ B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .

HY-P99884

Sasanlimab PF-06801591	PD-1/PD-L1	Inflammation/Immunology Cancer
Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with *PD-L1/PD-L2*, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .

HY-P990704

Rilvegostomig AZD-2936	PD-1/PD-L1 Transmembrane Glycoprotein	Cancer
Rilvegostomig (AZD-2936) is a bispecific humanized IgG1 antibody targeting *PD-1* and TIGIT. Rilvegostomig induces tumor growth inhibition and modulates the tumor immune microenvironment. Rilvegostomig exhibits anti-tumor activity in metastatic non-small cell lung cancer (without prior immune checkpoint inhibitor treatment). Rilvegostomig can be used in research related to metastatic non-small cell lung cancer and endometrial cancer .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of acute myeloid leukemia (AML) cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with *PD-1* blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-P99610

Ezabenlimab BI-754091	PD-1/PD-L1	Cancer
Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant K_d value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of *PD-1* with *PD-L1* and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against *PD-1* that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-P990961

Palverafusp alfa IMM-2510; SYN-2510	VEGFR PD-1/PD-L1	Cardiovascular Disease Inflammation/Immunology Cancer
Palverafusp alfa (IMM-2510; SYN-2510) is a *PD-L1/VEGF*-targeting IgG1κ type humanized antibody. Palverafusp alfa blocks PD-1/PD-L1 binding, relieves immune suppression, mediates PD-L1-directed antibody-dependent cellular cytotoxicity (ADCC). Palverafusp alfa blocks VEGF/VEGFR binding, inhibits angiogenic signaling, relieves VEGF-induced immune suppression. Palverafusp alfa reduces endothelial cell proliferation, enhances ADCC and antibody-dependent cellular phagocytosis (ADCP), inhibits tumor growth, reverses T cell immune suppression. Palverafusp alfa exhibits immune stimulatory, antiangiogenic, and anti-tumor activity in the tumor microenvironment. Palverafusp alfa can be used for the research of cancer, such as solid tumors, non-small cell lung cancer .

HY-P991079

Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)	PD-1/PD-L1	Cancer
Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.

HY-P991739

RC148	VEGFR PD-1/PD-L1	Cancer
RC148 is a humanized IgG1 bispecific antibody targeting VEGF and *PD-1. RC148 blocks PD-1-PD-L1* and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .

HY-P990828

Anti-PD-L1/B7-H1 Antibody (29E.2A3)	PD-1/PD-L1	Infection
Anti-PD-L1/B7-H1 Antibody (29E.2A3) is a kind of mouse IgG2b κ chimeric antibody inhibitor, targeting to human *PD-L1/B7-H1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can block the binding of PD-1* to PD-L1. Anti-PD-L1/B7-H1 Antibody (29E.2A3) can be used for the research of infection, such as hepatitis C virus (HCV) .

HY-P99048A

Sintilimab (Anti-PD-1) IBI308 (Anti-PD-1)	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (Anti-PD-1) (IBI308 (Anti-PD-1)) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to *PD-1* with a K_D value of 74 pM. Sintilimab (Anti-PD-1) blocks the interaction of *PD-1* with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab (Anti-PD-1) combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab (Anti-PD-1) can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99639

Geptanolimab Genolimzumab; APL-501; CBT-501; GB-226	PD-1/PD-L1	Cancer
Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer .

HY-P99887

Pimivalimab JTX-4014	PD-1/PD-L1	Cancer
Pimivalimab (JTX-4014) is a *PD-1* inhibitor. Pimivalimab can be used for the research of solid tumor .

HY-P990170

Anti-Mouse PD-L2/B7-DC Antibody (TY25)	Transmembrane Glycoprotein	Inflammation/Immunology
Anti-Mouse PD-L2/B7-DC Antibody (TY25) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse PD-L2/B7-DC. Anti-Mouse PD-L2/B7-DC Antibody (TY25) blocks PD-L2 binding to PD-1 and blocks PD-1 signaling. Anti-Mouse PD-L2/B7-DC Antibody (TY25) can be used for the researches of inflammation and immunology, such as conjunctivitis and transplantation .

HY-P991620

JS006	Transmembrane Glycoprotein	Cancer
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) .

HY-P991356

FAZ-053 LAE-005	PD-1/PD-L1	Cancer
FAZ-053 is a human monoclonal antibody (mAb) targeting *B7-H1/PD-L1/CD274. FAZ-053 inhibits* the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .

HY-P990716

Sabestomig AZD7789	PD-1/PD-L1 Tim3	Inflammation/Immunology
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting *PD-1* and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma .

HY-145771

PD-1/PD-L1-IN-20	PD-1/PD-L1	Cancer
PD-1/PD-L1-IN-20 (Example 21) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-20 blocks PD-1/PD-L1 with the IC₅₀ of 5.29 nM. PD-1/PD-L1-IN-20 can be used for the research of cancers, infectious diseases and autoimmune diseases .

HY-P992448

RC98	PD-1/PD-L1	Cancer
RC98 is a monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) and acts as a selective PD-L1 inhibitor. RC98 binds specifically to human and cynomolgus monkey PD-L1. RC98 blocks the interaction between PD-L1 and its receptor PD-1 to reverse T-cell inactivation mediated by PD-1/PD-L1 signaling. RC98 enhances the cytotoxic T-lymphocyte-mediated anti-tumor immune response against PD-L1-expressing tumor cells. RC98 can be used for the research of tumor immunity and solid tumors .

HY-P992062

Anti-Mouse CD80 Antibody (TKMG48)	PD-1/PD-L1	Inflammation/Immunology
Anti-Mouse CD80 Antibody (TKMG48) is an antibody that targets mouse CD80. By specifically binding to and disrupting the *CD80:PD-L1* complex to release PD-L1, Anti-Mouse CD80 Antibody (TKMG48) functions as an indirect *PD-1* agonist without blocking CD28 co-stimulation or CD80-CTLA4 binding. Anti-Mouse CD80 Antibody (TKMG48) inhibits T cell activation, reduces T cell effector functions and antigen-specific CD8 ⁺ T cell populations, and does not interfere with the differentiation, migration, antigen presentation or surface marker expression of dendritic cells. Anti-Mouse CD80 Antibody (TKMG48) significantly attenuates disease severity in mouse models of arthritis, spondyloarthritis, multiple sclerosis and Sjögren's syndrome, and its activity depends on the expression of PD-1 and PD-L1 .

HY-P992434

OSE-279	PD-1/PD-L1 SHP1 Interleukin Related	Cancer
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting *PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1* ligand binding, inhibits *PDL1*-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma .

HY-P992478

TY101	PD-1/PD-L1	Cancer
TY101 is an anti-PDCD1/PD-1/CD279 monoclonal antibody. TY101 binds to and inhibits PD-1 and its downstream signaling pathways .

HY-P992357

GNUV201	PD-1/PD-L1	Cancer
GNUV201 is a *PD-1* inhibitor with cross-reactivity in humans, mice and monkeys, which effectively blocks the *PD-1/PD-L1* interaction. GNUV201 activates T cells and restores their anti-tumor activity, effectively inducing tumor regression. GNUV201 can be used in the research of related diseases such as colorectal cancer, melanoma, pancreatic cancer and colon cancer .

HY-P992177

AI-025	PD-1/PD-L1	Inflammation/Immunology Cancer
AI-025 is an anti-PD-1 antibody. AI-061, a combination formulation of AI-025 and ONC-392 (HY-P990042), inhibits the downregulation of cell activation and proliferation mediated by PD-1 and CTLA-4, thereby restoring immune function and activating cytotoxic T lymphocyte-mediated immune responses against tumor cells. AI-025 can be used in cancer research .

HY-P992380

IBC-Ab002	PD-1/PD-L1	Neurological Disease
IBC-Ab002 is a humanized anti-PD-L1 monoclonal antibody with a modified Fc backbone that shortens its circulating half-life. IBC-Ab002 inhibits PD-L1, triggers immune responses by blocking the *PD-1/PD-L1* pathway, promotes the recruitment of myeloid-derived immune cells to the brain, enhances the clearance of toxic substances in the brain, improves neuronal function and reduces inflammation. IBC-Ab002 reduces the risk of accelerated onset of autoimmune diabetes in susceptible mice. IBC-Ab002 can be used in research related to Alzheimer's disease .

HY-P992351

ELB021	Inhibitory Antibodies	Infection Cancer
ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8 ⁺ T cell-mediated cytotoxicity. Independent of *PD-1* regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection .

HY-P990823

Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11)	PD-1/PD-L1	Infection Metabolic Disease Inflammation/Immunology Cancer
Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) is rat-derived IgG2b κ type antibody inhibitor, targeting to *PD-L1/B7-H1. Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) can block PD-L1/ B7-1 interactions and does not block PD-L1/PD-1* interactions. Anti-Mouse PD-L1/B7-H1 Antibody (10F.2H11) can be used for the researches of cancer, infection, immunology and metabolic disease, such as MB49 tumor, heart graft and diabetes .

Cat. No.	Product Name		Classification

HY-169392

D5B		DBCO
D5B is a potent and selective *PD-L1* inhibitor. D5B has been modified by DBCO. The EC₅₀ of D5B degrading PD-L1 in 4T1 and B16-F10 tumor cells are 5.4 μM and 6.2 μM, respectively. D5B can block PD-L1/PD-1 interaction and has anti-tumor activity .

HY-162356

PD-L1-IN-4		Azide
PD-L1-IN-4 (Compound X18) is an orally active *PD-L1* inhibitor that exhibits remarkable inhibitory activity against the PD-1/PD-L1 interaction (IC₅₀ = 1.3 nM) and enhances PD-L1 inhibitory effect on T cells (EC₅₀ = 152.8 nM). PD-L1-IN-4 can be used for the research of cancer .

Cat. No.	Product Name		Classification

HY-177801

XQ-P3 sodium		Aptamers
XQ-P3 sodium is an aptamer that binds to PD-L1. XQ-P3 can inhibit the PD-1/PD-L1 interaction and restore the function of T cells to detect and attack tumor cells.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks